|
1
|
Masaki Y, Kawabata H, Fujimoto S, Kawano
M, Iwaki N, Kotani T, Nakashima A, Kurose N, Takai K, Suzuki R and
Aoki S: Epidemiological analysis of multicentric and unicentric
Castleman disease and TAFRO syndrome in Japan. J Clin Exp Hematop.
59:175–178. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Castleman B, Iverson L and Menendez VP:
Localized mediastinal lymphnode hyperplasia resembling thymoma.
Cance. 9:822–830. 1956.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Dispenzieri A and Fajgenbaum DC: Overview
of Castleman disease. Blood. 135:1353–1364. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Simpson D: Epidemiology of Castleman
disease. Hematol Oncol Clin North Am. 32:1–10. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Oksenhendler E, Boutboul D, Fajgenbaum D,
Mirouse A, Fieschi C, Malphettes M, Vercellino L, Meignin V, Gérard
L and Galicier L: The full spectrum of Castleman disease: 273
Patients studied over 20 years. Br J Haematol. 180:206–221.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Cohen AB, Swaminathan A, Wang X, Zamora S,
Repucci MA, Kelly J, Hannan MD, Sepler D, Sridharma S, Orlando A,
et al: Clinical characteristics, treatment patterns, and overall
survival of real-world patients with idiopathic multicentric
Castleman disease. J Clin Oncol. 39 (Suppl 15)(S7048)2021.
|
|
7
|
Boutboul D, Fadlallah J, Chawki S, Fieschi
C, Malphettes M, Dossier A, Gérard L, Mordant P, Meignin V,
Oksenhendler E and Galicier L: Treatment and outcome of Unicentric
Castleman disease: A retrospective analysis of 71 cases. Br J
Haematol. 186:269–273. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wojtyś M, Piekarska A, Kunc M, Ptaszyński
K, Biernat W, Zaucha JM, Waloszczyk P, Lisowski P, Kubisa B and
Grodzki T: Clinicopathological comparison and therapeutic approach
to Castleman disease-a case-based review. J Thorac Dis.
11:4859–4874. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Muhammad T, Alkheder A, Mazloum A, Almooay
A, Naziha L and Shaheen M: Unicentric Castleman disease: A case
report of an atypical presentation and successful management. Int J
Surg Case Rep. 118(109688)2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Talat N, Belgaumkar AP and Schulte KM:
Surgery in Castleman's disease: A systematic review of 404
published cases. Ann Surg. 255:677–684. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hu S, Li Z, Wang H, Chen L, Ma Y, Zhu X,
Li J, Dong R, Yao W, Dong C, et al: Clinical features and treatment
outcomes of Castleman disease in children: A retrospective cohort
in China. Eur J Pediatr. 182:5519–5530. 2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
van Rhee F, Wong RS, Munshi N, Rossi JF,
Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, et al:
Siltuximab for multicentric Castleman's disease: A randomised,
double-blind, placebo-controlled trial. Lancet Oncol. 15:966–974.
2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang L, Zhao AL, Duan MH, Li ZY, Cao XX,
Feng J, Zhou DB, Zhong DR, Fajgenbaum DC and Li J: Phase 2 study
using oral thalidomide-cyclophosphamide-prednisone for idiopathic
multicentric Castleman disease. Blood. 133:1720–1728.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Carbone A, Borok M, Damania B, Gloghini A,
Polizzotto MN, Jayanthan RK, Fajgenbaum DC and Bower M: Castleman
disease. Nat Rev Dis Primers. 7(84)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mitsos S, Stamatopoulos A, Patrini D,
George RS, Lawrence DR and Panagiotopoulos N: The role of surgical
resection in Unicentric Castleman's disease: A systematic review.
Adv Respir Med. 86:36–43. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhang MY, Jia MN, Chen J, Feng J, Cao XX,
Zhou DB, Fajgenbaum DC, Zhang L and Li J: UCD with MCD-like
inflammatory state: Surgical excision is highly effective. Blood
Adv. 5:122–128. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
van Rhee F, Oksenhendler E, Srkalovic G,
Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S,
Streetly M, et al: International evidence-based consensus
diagnostic and treatment guidelines for unicentric Castleman
disease. Blood Adv. 4:6039–6050. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Abraham SS, Narayanan G, Thambi SM,
Vasudevan JA, Joy Philip DS, Purushothaman PN, Nair SG and Nair R:
Castleman disease: Experience from a single institution. Med Int
(Lond). 3(56)2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mohan M, Meek JC, Meek ME, Broadwater R,
Alapat D and van Rhee F: Combinatorial treatment for unresectable
unicentric Castleman disease. Eur J Haematol. 107:484–488.
2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhu SH, Yu YH, Zhang Y, Sun JJ, Han DL and
Li J: Clinical features and outcome of patients with HIV-negative
multicentric Castleman's disease treated with combination
chemotherapy: A report on 10 patients. Med Oncol.
30(492)2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Seo HY, Kim EB, Kim JW, Shin BK, Kim SJ
and Kim BS: Complete remission in a patient with human herpes
virus-8 negative multicentric Castleman disease using CHOP
chemotherapy. Cancer Res Treat. 41:104–107. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
van Rhee F and Stone K: Storming the
Castle with TCP. Blood. 133:1697–1698. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kaneko H, Ohkawara T, Aragane H, Ohkawara
Y and Taniwaki M: Clinicopathological analysis of a case with
mesenteric solitary Castleman's disease: Diagnostic value of
radiological findings. Int Surg. 92:272–275. 2007.PubMed/NCBI
|
